Advertisement

Immunomodulation: Facts and Interpretations

  • A. Brand
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 36)

Abstract

Blood transfusions expose the recipient to multiple antigens and immunisation against a particular antigen occurs simultaneously with suppression towards other antigens. Moreover, transfusions can stimulate or suppress the host immunity against environmental antigens.

Keywords

Blood Transfusion Donor Cell Postoperative Infection Donor Lymphocyte Infusion Graft Versus Leukaemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fast L.D. Recipient elimination of allogeneic lymphoid cells: donor CD4+ cells. are effective alloantigen-presenting cells. Blood, 2000;96:1 144–48.Google Scholar
  2. 2.
    Opelz G, Sengar DF’P, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1971;5:253–59.Google Scholar
  3. 3.
    Opelz G, Vanrenterhem Y, Kirste G. GrayDW.etal. Prospective evaluation of pretransplant blood transfusion in cadaver kidney recipients. Transplantation 1997, 63:964–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Opelz G. Terasaki Pl. Improvement of kidney-graft survival with increased numbers of transfusions. N Engl J Med 1978;299:799–803.PubMedCrossRefGoogle Scholar
  5. 5.
    Lagaaij EL, Henneman IP, Ruigrok M, et al. Effect of one-HLA-DR antigen matched and completely FILA-DR mismatched blood transfusions on survival of heart and kidney allografts. New Eng J Med 1989;321:701–05.PubMedCrossRefGoogle Scholar
  6. 6.
    Vervoordeldonck SF, Doumaid K. Remmerswaal M et al. Long-term detection of microchimaerism in peripheral blood after pretransplantation blood transfusion. Br J Haematol 1998:102:1004–09.CrossRefGoogle Scholar
  7. 7.
    Mincheff MS, Meryman HT, Kapoor V, Alsop P, Wotzel M. Blood Transfusion and immunomodulation a possible mechanism. Vox Sang 1993;65:18–24.PubMedCrossRefGoogle Scholar
  8. Mc Donald JC, Adamashvili I. Soluble HLA. Human Immunology 1998;59:387–403.Google Scholar
  9. 9.
    Hodge G, Lloyd JV. Hodge S, Story C, Han P. Functional lymphocyte immunophenotypes observed in thalassaemia and haemophilia patients receiving current blood product preparations. Br J Haematol 1999,105:817–25.PubMedCrossRefGoogle Scholar
  10. 10.
    Hay CRM, Mc Evoy P, Duggan-Keen M. Inhibition of lymphocyte IL-3 receptor expression by factor VIII concentrate: A possible cause of immunosuppression in haemophiliacs. Br J Haematol 1990;75:278–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Young NT, Roelen DL, Iggo N, et al. Effect of one HLA-haptotype matched and FILA mismatched blood transfusions on recipient T lymphocyte allorepertoires. Transplantation 1997;63:1160–65.PubMedCrossRefGoogle Scholar
  12. van der Mast BJ, Hornstra N, Ruigrok MB, Claas FJH, van Rood JJ, Lagaaij EL. Transfusion-associated graft-versus-host disease in immunocompetent patients: a self protective mechanism. Lancet 1994;343:753Google Scholar
  13. 13.
    Kolb Hi. Schattenberg A. Goldman JM, et al. Graft-versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041–50.PubMedGoogle Scholar
  14. 14.
    Hirano N. Takanashi T. Ohtake S et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996;10:1 168–76.Google Scholar
  15. 15.
    Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relaps of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261–68.PubMedGoogle Scholar
  16. 16.
    Turner JH, Hutchinson DL, Petricciani JC. Chimerism following fetal transfusion: report of leukocyte hybridization and infant with acute lymphocytic leukaemia. Scand J Haematol 1973:10:358–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci USA 1996;93:705.PubMedCrossRefGoogle Scholar
  18. 18.
    Victor HE, Hallensleben E, van Bree SPMJ, et al. Survival of donor cells 25 years after intrauterine transfusion. Blood 2000;95:2709–14.Google Scholar
  19. 19.
    Jones WR. Immunological aspects of intrauteriene transfusion. BM.I 1968;3:280.Google Scholar
  20. 20.
    Fowler R, Schubert WK. West CD. Acquired partial tolerance to homologous skin grafts in the human infant at birth. Ann NY Acad Sci 1960;87:403.PubMedGoogle Scholar
  21. 21.
    Lee TH. Paglieroni T, Ohto H, Holland PV, Busch MP. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood 1999;93:3127–39.PubMedGoogle Scholar
  22. 22.
    Jungi TW, Nydegger UE. Proposed mechanisms of action of IVIg in autoimmune diseases. Transfus Sci 1992;13:267–300.CrossRefGoogle Scholar
  23. 23.
    Brand A, Vuist WM, van Schalk IN, Vermeulen M. In vitro investigation of immunoglobulin treatment mechanisms in autoimmune diseases. Clin Exper Rheumatol 1996;14 (suppl. 15):27–30.Google Scholar
  24. Ghetie V, Ward SE: FcRn: the MHC cluss I-related receptor that is more than an lgG transporter. Immunol Today 1997:592–95.Google Scholar
  25. 25.
    Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic ipurpura by high-dose intravenous gammaglobulin. N Engl J Med 1982:306:1254–58.PubMedCrossRefGoogle Scholar
  26. 26.
    Vermeulen M, van der Meché FGA, Speelman JD, Weber A, Busch HEM. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985;70:317–26.PubMedCrossRefGoogle Scholar
  27. 27.
    Blumberg N, Heal JM, Evidence for plasma-mediated immunomodulation transfusions of plasma-rich blood components are associated with a greater risk of acquired immunodeficiency syndrome than transfusions of red blood cells alone. Transplant Proc 1988;20:1138–42.PubMedGoogle Scholar
  28. 28.
    Vamvakas EC. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-Alloimmunization and refractoriness to random-donor platelet transfusions. Transf Med Rev 1998;12:258–70.CrossRefGoogle Scholar
  29. 29.
    Co-operative study group. Leukocyte Reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861–69.CrossRefGoogle Scholar
  30. 30.
    Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunisation and refractoriness: a randomized prospective study. Blood 1995;85:824–28.PubMedGoogle Scholar
  31. 31.
    Lazarus AH, Crow AR, Semple JW, et al. Induction of a secundary human anti-HLA alloimmune response in severe combined immunodeficient mice engrafted with human lymphocytes. Transfusion 1997;37:1192–99.PubMedCrossRefGoogle Scholar
  32. 32.
    Brand A. Houbiers JGA. Clinical Studies of Blood Transfusion and Cancer. In: Vamvakas EC, Blajchman MA, eds Immunomodulatory Effects of Blood Transfusion. AABB Press, 1999:145–90.Google Scholar
  33. 33.
    Heis MM, Jauch KW, Delanoff C, et al. Blood transfusion modulated tumor recurrence: A randomized study of autologous versus homologous blood transfusion in colorectal cancer. J Clin Oncol 1994;12:1859–67.Google Scholar
  34. 34.
    Busch ORC, Hop WJC, van Papendrecht MAWH, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993;328:1372–76.PubMedCrossRefGoogle Scholar
  35. 35.
    Houbiers JGA, Brand A, van de Watering LMG, et al. Randomized controlled trial comparing transfusion of leukocyte-depleted or butfy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344:573–78.PubMedCrossRefGoogle Scholar
  36. 36.
    Vamvakas E. Transfusion-associated cancer recurrence and infection: Meta-analysis of the randomized controlled clinical trials. Transfusion 1996;36:175–86.CrossRefGoogle Scholar
  37. 37.
    Smith MEF, Bodmer WF, Bodmer JG, Selective loss of FILA- A,B and C locus products in colorectal adenocarcinoma. Proc Natl Acad Sci 1989;86:5557–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell fucntion following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg. 1992;79:513–16.PubMedCrossRefGoogle Scholar
  39. 39.
    Jensen LS, Kissmeyer-Nielsen P, Wolff B. et al. Randomized comparison of leukocyte-depleted verus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996;348:841–45..PubMedCrossRefGoogle Scholar
  40. van de Watering LMG, Hermans J, Houbiers JGA et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery. Am Heart Assoc 1998:562–68.Google Scholar
  41. 41.
    Tartter PI, Mohandas K, Azar P, Endres J, Kaplan J. Spivack M. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998;176:462–66.PubMedCrossRefGoogle Scholar
  42. 42.
    Titlestad IL, Ebbesen LE, Ainsworth A, Lillevang ST, Qvist N. Georgsen J. Leukocyte depletion and complications to colorectal surgery. Vox Sang 2000. (Abstract ISBT).Google Scholar
  43. 43.
    Blajchman MA. Allogeneic blood transfusions, immunomodulation and postoperative bacterial infection: Do we have the answers yet? Editorial. Transfusion 1997; 37:121–25.CrossRefGoogle Scholar
  44. 44.
    Editorial. Block the phagocytes. Lancet 1993:342:199.CrossRefGoogle Scholar
  45. 45.
    Swank RL, Seaman GVF. Microfiltration and microemboli: a history. Transfusion 2000;40:114–19.PubMedCrossRefGoogle Scholar
  46. 46.
    International Forum. Does a relationship exist between massive blood transfusions and the adult repiratory distress syndrome? If so, what are the best preventive measures? Vox Sang 1977;32:311–20.CrossRefGoogle Scholar
  47. 47.
    Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334–48.PubMedCrossRefGoogle Scholar
  48. 48.
    Nielsen HJ, Hammer JH, Moesgaard F, Kehlet H. Ranitidine prevents postoperative transfusion-induced depression of delayed hypersensitivity. Surgery 1989;105:711–19.PubMedGoogle Scholar
  49. 49.
    Ertel W, Keel M. Neidhardt R, Steckholzer U, Kremer JP, Ungethuem U. Trentz O. Inhibition of the defense system stimulating interleukin-12 interferon-(pathway during critical illness. Blood 1997;89:1612–20.PubMedGoogle Scholar
  50. 50.
    Kirkley SA. Cowles J. Pellegrini VD, Harris CM. Boyd AD. Blumberg N. Blood transfusion and total joint replacement surgery: 7’ helper 2 (TH2) cytokine secretion and clinical outcome. Transplant Med 1998:8:195–204.CrossRefGoogle Scholar
  51. 51.
    Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994; 12:991–1045.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2001

Authors and Affiliations

  • A. Brand
    • 1
  1. 1.Blood Bank Leiden-Haaglanden and Dept. of Immunohaematology and Blood TransfusionLeiden University Medical CentreLeidenNL

Personalised recommendations